• 1
    Middleton H, Shaw I, Hull S, Feder G. NICE guidelines for the management of depression. BMJ 2005; 330: 2678.
  • 2
    Mulrow CD, Williams JW Jr, Trivedi M et al. (Prepared by the San Antonio Evidence-Based Practice Center based at The University of Texas Health Science Center at San Antonio under Contract 290-97-0012). Treatment of Depression: Newer Pharmacotherapies. Evidence Report/Technology Assessment No. 7. AHCPR Publication No. 99-E014. Rockville, MD: Agency for Health Care Policy and Research, 1999. (accessed on March 24 2005).
  • 3
    NICE Guideline. National Collaborating Centre for Mental Health. Depression: management of depression in primary and secondary care. December, 2004. (accessed on October 24 2005).
  • 4
    Paykel ES, Hollyman JA, Freeling P, Sedgwick P. Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Disord 1988; 14: 8395.
  • 5
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (Text Revision).Washington, DC: American Psychiatric Association, 2000.
  • 6
    Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978; 35: 77382.
  • 7
    Judd LL, Rapaport MH, Paulus MP, Brown JL. Subsyndromal symptomatic depression: a new mood disorder? J Clin Psychiatry 1994; 55 (Suppl.): 1828.
  • 8
    Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord 1997; 45: 1930.
  • 9
    Rapaport MH, Judd LL, Schettler PJ et al. A descriptive analysis of minor depression. Am J Psychiatry 2002; 159: 63743.
  • 10
    Sadek N, Bona J. Subsyndromal symptomatic depression: a new concept. Depress Anxiety 2000; 12: 309.
  • 11
    Kessler RC, Demler O, Frank RG et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005; 352: 251523.
  • 12
    Judd LL, Paulus MP, Wells KB, Rapaport MH. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry 1996a; 153: 14117.
  • 13
    Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord 1997; 45: 517 (discussion 17–8).
  • 14
    Bech P. Acute therapy of depression. J Clin Psychiatry 1993; 54 (Suppl.): 1827 (discussion 28).
  • 15
    Mulrow CD, Williams JW Jr, Chiquette E et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med 2000; 108: 5464.
  • 16
    Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 87180.
  • 17
    Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 2002; 58: 169222.
  • 18
    Wong DT, Bymaster FP, Mayle DA et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 1993; 8: 2333.
  • 19
    Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002; 36: 38390.
  • 20
    Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63: 30815.
  • 21
    Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002; 63: 22531.
  • 22
    Goldstein DJ, Lu Y, Detke MJ et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24: 38999.
  • 23
    Andorn AC, Mallinckrodt CH, Raskin H et al. Efficacy of duloxetine in patients with mild, moderate, or severe depressive symptoms. Poster presented at: Annual Convention of the American Psychological Association, 2005 August 18; Washington, DC.
  • 24
    Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 5662.
  • 25
    Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 27896.
    Direct Link:
  • 26
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
  • 27
    Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl. 20): 2233 (quiz 34–57).
  • 28
    Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I. History, rationale, and description. Arch Gen Psychiatry 1992; 49: 6249.
  • 29
    Guy W (Public Health Service Alcohol, Drug Abuse, and Mental Health Administration). ECDEU Assessment Manual for Psychopharmacology Revised, 1976. Rockville, MD: U.S. Department of Health, Education, and Welfare, 1976: 21722. (DHEW Publication No: [ADM] 76-338).
  • 30
    Barsky AJ, Wyshak G, Klerman GL. Hypochondriasis. An evaluation of the DSM-III criteria in medical outpatients. Arch Gen Psychiatry 1986; 43: 493500.
  • 31
    DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998; 86: 1026.
  • 32
    Nemeroff CB, Schatzberg AF, Goldstein DJ et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002; 36: 10632.
  • 33
    Stewart JW, Quitkin FM, Liebowitz MR et al. Efficacy of desipramine in depressed outpatients. Response according to research diagnosis criteria diagnoses and severity of illness. Arch Gen Psychiatry 1983; 40: 2027.
  • 34
    Dunlop SR, Dornseif BE, Wernicke JF, Potvin JH. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull 1990; 26: 17380.
  • 35
    Khan A, Brodhead AE, Kolts RL, Brown WA. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005; 39: 14550.
  • 36
    Pande AC, Sayler ME. Severity of depression and response to fluoxetine. Int Clin Psychopharmacol 1993; 8: 2435.
  • 37
    Stewart JW, McGrath PJ, Liebowitz MR et al. Treatment outcome validation of DSM-III depressive subtypes. Clinical usefulness in outpatients with mild to moderate depression. Arch Gen Psychiatry 1985; 42: 114853.
  • 38
    Fabre LF, Putman HP III. A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J Clin Psychiatry 1987; 48: 4068.
  • 39
    Elkin I, Shea MT, Watkins JT et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 1989; 46: 97182 (discussion 983).
  • 40
    Peveler R, Kendrick T for the THREAD Study Group. Selective serotonin reuptake inhibitors: THREAD trial may show way forward. BMJ 2005; 330: 4201.
  • 41
    Bagby RM, Ryder AG, Schuller DR, Marshall MB. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry 2004; 161: 216377.
  • 42
    Williams JBW. Standardizing the Hamilton Depression Rating Scale: past, present, and future. Eur Arch Psychiatry Clin Neurosci 2001; 251 (Suppl. 2): II612.
  • 43
    Khan A, Brodhead AE, Kolts RL. Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: a replication analysis. Int Clin Psychopharmacol 2004; 19: 15760.
  • 44
    Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ. Time course of depression-symptom improvement during treatment with duloxetine. Depress Anxiety 2005; 21: 1707.